Detalles de la búsqueda
1.
High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11.
Environ Toxicol
; 39(7): 4035-4046, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642004
2.
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
BMC Cancer
; 23(1): 753, 2023 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37580661
3.
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
J Neurooncol
; 165(2): 301-312, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995007
4.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Lancet Oncol
; 23(2): 220-233, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35038432
5.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Lancet Oncol
; 21(6): 832-842, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416073
6.
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Cancer Sci
; 111(2): 679-686, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31828849
7.
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
J Transl Med
; 17(1): 52, 2019 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30791921
8.
Co-expression of NF-κB-p65 and phosphorylated NF-κB-p105 is associated with poor prognosis in surgically resectable non-small cell lung cancer.
J Cell Mol Med
; 22(3): 1923-1930, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29363879
9.
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
J Transl Med
; 16(1): 93, 2018 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29642919
10.
Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
Med Sci Monit
; 24: 8207-8212, 2018 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30429449
11.
[A multicenter, randomized, controlled, phase â ¢ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Zhonghua Zhong Liu Za Zhi
; 38(1): 23-7, 2016 Jan.
Artículo
en Zh
| MEDLINE | ID: mdl-26796802
12.
Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
J Clin Oncol
; : JCO2400731, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38822758
13.
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Cancer Med
; 13(10): e7203, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38769930
14.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Cancer Commun (Lond)
; 44(4): 455-468, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421881
15.
[The efficacy and adverse effects of individualized treatment for elderly patients with epidermal growth factor receptor wild-type non-small cell lung cancer under the guidance of molecular markers].
Zhonghua Jie He He Hu Xi Za Zhi
; 36(9): 679-83, 2013 Sep.
Artículo
en Zh
| MEDLINE | ID: mdl-24423823
16.
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
Eur J Cancer
; 190: 112936, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393762
17.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer
; 184: 107355, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37677918
18.
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Nat Med
; 29(2): 473-482, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36732627
19.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
EClinicalMedicine
; 62: 102106, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37593227
20.
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Signal Transduct Target Ther
; 8(1): 301, 2023 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574511